Multipronged Approaches for HPV16+ Cancers

Beyond anti–PD-1 therapy as a mainstay, additional strategies are being developed for HPV-associated cancers. Emerging data from two ongoing trials have shown some early efficacy with vaccines directed at HPV16-specific E6 and E7 viral oncoproteins, as well as with other therapies targeting different facets of antitumor immunity.